Abstract:Spinal muscular atrophy (SMA) is a genetic disorder that causes progressive degeneration of lower motor neurons and the subsequent loss of muscle function throughout the body. It is the second most common recessive disorder in individuals of European descent and is present in all populations. Accurate tools exist for diagnosing SMA from short read and long read genome sequencing data. However, there are no publicly available tools for GRCh38-aligned data from panel or exome sequencing assays which continue to be used as first line tests for neuromuscular disorders. We therefore developed and extensively validated a new tool - SMA Finder - that can diagnose SMA not only in genome, but also exome and targeted sequencing samples aligned to GRCh37, GRCh38, or T2T-CHM13. It works by evaluating aligned reads that overlap the c.840 position of and in order to detect the most common molecular causes of SMA. We applied SMA Finder to 16,626 exomes and 3,911 genomes from heterogeneous rare disease cohorts sequenced at the Broad Institute Center for Mendelian Genomics as well as 1,157 exomes and 8,762 targeted sequencing samples from Tartu University Hospital. SMA Finder correctly identified all 16 known SMA cases and reported nine novel diagnoses which have since been confirmed by clinical testing, with another four novel diagnoses undergoing validation. Notably, out of the 29 total SMA positive cases, 21 had an initial clinical diagnosis of muscular dystrophy, congenital myasthenic syndrome, or congenital myopathy. This underscored the frequency with which SMA can be misdiagnosed as other neuromuscular disorders and confirmed the utility of using SMA Finder to reanalyze phenotypically diverse neuromuscular disease cohorts. Finally, we evaluated SMA Finder on 198,868 individuals that had both exome and genome sequencing data within the UK Biobank (UKBB) and found that SMA Finder’s overall false positive rate was less than 1 / 200,000 exome samples, and its positive predictive value (PPV) was 96%. We also observed 100% concordance between UKBB exome and genome calls. This analysis showed that, even though it is located within a segmental duplication, the most common causal variant for SMA can be detected with comparable accuracy to monogenic disease variants in non-repetitive regions. Additionally, the high PPV demonstrated by SMA Finder, the existence of treatment options for SMA in which early diagnosis is imperative for therapeutic benefit, as well as widespread availability of clinical confirmatory testing for SMA, may warrant the addition of to the ACMG list of genes with reportable secondary findings after genome and exome sequencing.

GARS-related Disease in Infantile Spinal Muscular Atrophy: Implications for Diagnosis and Treatment

Infantile‐onset CMT2D/dSMA‐V in a Chinese Family with Parental Germline Mosaicism for a Novel Mutation in the GARS1 Gene

[Clinical characteristics and genetics functional analysis of two children with Spinal muscular atrophy]

Rare homozygous disease-associated sequence variants in children with spinal muscular atrophy: A phenotypic description and review of the literature

A Homozygous Missense Variant in the YG Box Domain in an Individual with Severe Spinal Muscular Atrophy: a Case Report and Variant Characterization

Detecting missed diagnoses of spinal muscular atrophy in genome, exome, and panel sequencing datasets

Discovery of specific mutations in spinal muscular atrophy patients by next-generation sequencing

Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular Atrophy

[Mutation Analysis of SMN1 Gene in Patients with Spinal Muscular Atrophy].

High-throughput Screening Reveals Novel Mutations in Spinal Muscular Atrophy Patients

Insights into phenotypic variability caused by GARS1 pathogenic variants

Delayed Diagnosis of Spinal Muscular Atrophy in Two Chinese Families due to Novel SMN1 Deletions

Gene therapy in spinal muscular atrophy

Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

The Clinical Heterogeneity of Spinal Muscular Atrophy with Respiratory Distress Type 1 (SMARD1)-A Report of Three Cases, Including Twins

[Molecular analysis of survival motor neuron gene in 338 suspicious children patients with spinal muscular atrophy].

Compound Heterozygous Mutation in Two Unrelated Cases of Chinese Spinal Muscular Atrophy Patients

Molecular analysis of SMN2, NAIP, and GTF2H2 gene deletions and relationships with clinical subtypes of spinal muscular atrophy

Treatment strategies for patients with spinal muscular atrophy

In Search of Spinal Muscular Atrophy Disease Modifiers

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges